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Effect of mineralocorticoid replacement therapy on renal acid-
base homeostasis in adrenalectomized patients. Chronic balance
studies were performed in six adrenalectomized patients to in-
vestigate the renal and systemic acid-base consequences of mm-
eralocorticoid deficiency in the absence of either glucocorticoid
deficiency or parenchymal renal disease. Constant glucocorti-
coid replacement was provided with dexamethasone, 750 to 875
gIday, administered orally. Creatinine clearance averaged 98
8 mI/mm/i .73 m2. Following a control period, mineralocorticoid
replacement with fiudrocortisone (100 to 200 gIday) was either
discontinued (N = 3) or initiated (N = 2). In an additional pa-
tient, mineralocorticoid replacement was initiated and sustained
(5 days) by continuous i.v. infusion of aldosterone, at a dose ap-
proximating the normal secretion rate (120 .tg/day). Net acid ex-
cretion (NAE) and plasma total carbon dioxide decreased in
each patient in whom mineralocorticoid was discontinued and
increased in each patient in whom mineralocorticoid was initiated.
The cumulative change in NAE (NAE) independent of direc-
tion averaged 66 20 mEq (P < 0.05) by the fifth experimental
day in the six patients, and the corresponding change in plasma
total CO2 averaged 1.2 0.3 mmoles/liter (P <0.02). The mag-
nitude of NAE correlated with the basal rate of NAE (r =
0.87, P < 0.05), which averaged 0.9 0.1 mEq/kg body wt
per day. The change in plasma total CO2 correlated with NAE(r = 0.83, P < 0.05). The changes in NAE correlated posi-
tively with the corresponding changes in sodium balance and
negatively with the corresponding changes in potassium balance.
These findings provide the first evidence that renal acidification
is under tonic stimulation by mineralocorticoid at levels not ex-
ceeding those in normal subjects ingesting acid-producing diets
of normal sodium and potassium content. The extent to which
the tonic stimulation of renal acidification is mediated by a di-
rect effect of mineralocorticoid on renal hydrogen ion transport
or by an indirect effect dependent on altered renal sodium and/or
potassium transport requires further investigation. The findings
implicate mineralocorticoid deficiency as a significant renal aci-
dosis-producing condition not dependent on the presence of
renal disease or glucocorticoid deficiency, and potentially ampli-
fied when endogenous acid production is increased by diet or
disease.
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Effet du traitement substitutif par les minéralocorticoldes sur
l'homéostasie rénale acido-basique chez les malades surrénalecto-
misés. Des bilans ont été réalisés chez six malades surrénalecto-
misés afin d'étudier les consequences acido-basiques du deficit
en minéralocorticoldes en l'absence soit de deficit en glucocor-
ticoides ou de maladie rénale parenchymateuse. Un remplace-
ment constant des glucocorticoldes a été réalisé par Ia dexa-
méthasone, 750 a 875 pg/jour, par voie orale. La clearance de Ia
créatinine était en moyenne de 98 8 mI/mm/I, 73 m2. Après une
période contrôle le remplacement des minéralocorticoides par Ia
fludrocortisone (100 a 200 pg/jour) a été soit arrCté (N 3) soit
commence (N = 2). Chez un autre malade le reniplacement des
minéralocorticoides a été commence et prolongé au moyen
d'une perfusion intraveineuse d'aldostérone a une dose proche
du debit de sécrétion normal (120 pg/jour). L'excrétion nette
d'acide (NAE) et le CO2 total du plasma ont diminué chez
tous les malades chez qui les minéralocorticoides ont été
arrétés et augmenté chez tous les malades chez lesquels les mm-
éralocorticoides ont été commences. La modification cumulée
de NAE (NAE), indépendamment du sens, était en moyenne
de 66 20 mEq (P < 0,05) au cinquième jour experimental chez
les six malades et Ia modification correspondante de Ia CO2 total
du plasma était en moyenne de 1,2 0,3 mmoles/litre (P < 0,02).
L'importance de ILNAE était corrélée avec le debit basal de
NAE (r = 0,87, P < 0,05) qui était en moyenne de 0,9 0,1 mEq/
kg de poids corporel par jour. Le modification de Ia CO2 to-
tal du plasma était corrélé avec 4NAE (r = 0,83, P <
0,05). Les modifications de NAE étaient corrélées positive-
ment avec les modifications correspondantes du bilan du so-
dium et négativement avec les modifications du bilan du potas-
sium. Ces constatations apportent pour la premiere fois Ia pre-
uve que l'acidification rénale est sous l'influence tonique de Ia
stimulation par les minéralocorticoides a des concentrations qui
ne dépassent pas celles des sujets normaux qui ingèrent des ré-
gimes générateurs d'acide et dont les contenus en sodium et po-
tassium sont normaux. La mesure dans laquelle Ia stimulation
tonique de l'acidification rénale a pour médiateur un effet direct
des minéralocorticoides sur le transport renal de l'ion hydrogène
ou bien un effet indirect dépendant des modifications do trans-
port du sodium et/ou du potassium nécessite d'autres etudes.
Ces constatations indiquent que Ic deficit en minéralocorticoides
est une situation qui determine une acidose rénale in-
dépendamment de Ia presence d'une maladie rénale ou d'un
deficit en glucocorticoIdes. L'acidose est plus importante quand
la production endogène d'acide est augmentée par l'alimentation
ou une maladie.
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In normal humans, the administration of mineral-
ocorticoid hormones that possess minimal glucocor-
ticoid activity results in agumentation of renal hy-
drogen ion secretion [1—7]. Acute administration of
aldosterone in large amounts to normal subjects re-
sults within hours in a decrease in urine pH [3—6]
and an increase in net acid excretion [3, 4, 6, 7].
Chronic administration of large amounts of aldoste-
rone results in a sustained increase in plasma bi-
carbonate concentration and pH indicative of the
development of metabolic alkalosis [8].
It has not been established whether mineral-
ocorticoid hormones at normal plasma concentra-
tions modulate renal acidification and systemic
acid-base equilibrium in normal adult humans. Al-
dosterone deficiency has been implicated in the
pathogenesis of renal metabolic acidosis in humans
with renal diseases [9], but whether renal acidosis
occurs in humans with aldosterone deficiency who
do not have renal disease has not been conclusively
determined. Renal metabolic acidosis has been re-
ported in infants and children with hypoaldosteron-
ism secondary to defects in adrenal steroid biosyn-
thesis (for example, 21 13-hydroxylase deficiency)
[10] and in children with inherited renal unrespon-
siveness to aldosterone (so-called pseudohypo-
aldosteronism) [11], but critical evaluations of acid-
base status after the affected children have reached
adulthood have not been reported. In adult patients
with Addison's disease or bilateral adrenalectomy,
it has been reported that systemic acid-base equilib-
rium is maintained 'normal" without mineral-
ocorticoid replacement therapy, provided that
glucocorticoid replacement therapy is adequate,
renal function is unimpaired by intrinsic renal dis-
ease, and salt intake is liberal or unrestricted [12,
13].
Analysis of the reported data in adrenalectomized
patients maintained on glucocorticoid therapy with-
out mineralocorticoid replacement does not compel
the conclusion that acid-base equilibrium is decid-
edly normal [12]. It is possible that plasma bicarbo-
nate concentration is regulated at a significantly
lower level during mineralocorticoid deficiency
than it is in the mineralocorticoid-replete state, yet
the resultant mild degree of metabolic acidosis
might remain unrecognized unless plasma bicarbo-
nate is compared in both states inasmuch as inter-
individual variation in plasma bicarbonate concen-
tration in normal subjects is large [14, 15]. In adult
subjects with selective mineralocorticoid deficiency
who do not have intrinsic renal disease, there ap-
pear to be no reported studies in which systemic
acid-base equilibrium and renal acid-base homeo-
stasis have been critically evaluated in the same
subjects with and without mineralocorticoid thera-
py under controlled study conditions, with particu-
lar attention to constancy of dietary acid load. The
present studies were carried out to further investi-
gate the acid-base effects of selective mineral-
ocorticoid deficiency in such subjects.
Methods
The experimental protocol consisted of either dis-
continuation or institution of replacement mineral-
ocorticoid therapy in six adult adrenalectomized pa-
tients studied under metabolic balance conditions.
The studies were performed at least 1 year follow-
ing surgical removal of both adrenal glands for
treatment of carcinoma of the breast (patients 1—3),
Cushing's syndrome (patients 4 and 6), or primary
aldosteronism (patient 5). None of the patients had
historical or laboratory evidence of renal disease
(Table 1). The studies were carried out in the Gen-
eral Clinical Research Centers at Moffitt Hospital
and San Francisco General Hospitals, University of
California, San Francisco. The protocols were ap-
proved by the Committee on Human Research, and
each patient gave informed consent.
The change in mineralocorticoid therapy was
made after acid-base and electrolyte balance had
been achieved with each patient receiving a con-
stant diet and constant glucocorticoid replacement
therapy. Glucocorticoid was provided as dexa-
methasone (Merck, Sharp and Dohme), 750 j.tg (pa-
tients 1—3, 5, 6) or 875 jsg (patient 4), administered
orally once daily. During the specified periods of
mineralocorticoid replacement therapy (Table 1),
mineralocorticoid was provided as fludrocortisone
(Squibb), 100 to 200 g, administered orally once
daily (patients 1—5), ord-aldosterone (Ciba), 120 jsg,
administered i.v. by constant infusion over 24 hours
each day (patient 6). The daily dose of mineral-
ocorticoid was constant in each patient throughout
the specified period.
The conditions of study in each patient are sum-
marized in Table 1. A control period of 4 to 10 days'
duration (average, 7 days) was initiated following an
equilibration period of variable duration required
for achievement of acid-base and electrolyte bal-
ance on the specified constant regimen of whole
food diet and steroid administration. The entire dai-
ly diet was ingested by each patient with the ex-
ception of patient 3 in whom dietary noncompliance
necessitated termination of study following 3 days
of mineralocorticoid discontinuation.
Potassium intake was constant in each study and
ranged from 1.0 to 1.6 mEq/kg body wt per day
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among the subjects (Table 1). Sodium intake was
constant during the equilibration and control peri-
ods in all studies and ranged from 1.1 to 1.9 mEq/kg!
day in the three subjects (patients 1—3) who were
receiving mineralocorticoid replacement during
these periods, and from 2.9 to 3.1 mEq/kg/day in the
three patients (patients 4—6) who were not receiving
mineralocorticoid replacement during these peri-
ods. In one subject (patient 2), sodium intake was
increased simultaneous with discontinuation of
mineralocorticoid therapy, in an attempt to mini-
mize negative sodium balance resulting from renal
sodium wasting. Sodium intake was also increased
in patient 1, but not until an 8-day period of mineral-
ocorticoid deficiency had occurred without change
in sodium intake (Table 1). In two patients (patients
4 and 5), sodium intake was decreased simultane-
ously with institution of mineralocorticoid therapy,
in an attempt to minimize positive sodium balance
resulting from renal sodium retention. Adjustment
of sodium intake was effected without change in
composition of foodstuffs by adjustment of the
amount of sodium chloride administered as weighed
tablets supplementing the diet. Intrinsic diet sodium
and potassium content was calculated by a re-
search dietitian from standard food composition ta-
bles [16]; previous studies from this laboratory have
demonstrated close correspondence between calcu-
lated and analyzed estimates of dietary electrolyte
composition [17].
Analytical procedures used in this laboratory
have previously been described [9]. Urinary al-
dosterone-18-glucuronide was measured by radio-
immunoassay [18]. Statistical analysis was by linear
regression and Student's t test [19]. Estimates of
variance are reported as
Results
Summary of results in patient no. 1. Figure 1 de-
picts the results of a representative study of the ef-
fect of mineralocorticoid discontinuation. During
the control period, the mean value of urinary net
acid excretion was 80 mEq/day, and the daily val-
ues differed from the mean by no more than 9 mEq/
day. On the first day following discontinuation of
mineralocorticoid therapy, net acid excretion de-
creased by 38 mEq from the mean control value.
Subsequently, the daily values of net acid excretion
remained below control but gradually increased to-
ward control. By day 8, the cumulative reduction in
net acid excretion (4NAE) from the mean control
value was 196 mEq. During the final 3 days, net acid
excretion returned to control values, and no further
cumulative reduction in net acid excretion oc-
curred. This apparent reestablishment of acid-base
Table 1. Biochemical data and protocol conditions in adrenalectomized patients without renal diseases
Patient no.,
age (yr), sex,
wt (kg)
Study
days
Steroid doseb Intake
gIday mEq/kg/day Creatinine
clearance
Fludro Aldo Sodium Potassium ml/min/I.73m2
Urinary
aldosterone
p.glday
Plasma renin activity
nglrnllhr
Dex Recumbent Upright
l,49,F,67 1—10
11—18
19—21
750
750
750
Mjneralocortjcojd discontinuation studies
100 0 1.5 1.3 108
0 0 1.5 1.3
0 0 6.8 1.3
<1
<1
<1
0.4 1.1
3.3 9.5
— 2.4
2,60,F,63 1—8
9—22
750
750
200 0 1.9 1.6 92
0 0 5.1 1.6
<1
<1
2.9 8.4
2.4 19.0
3, 54, F, 62 1—5
6—8
750
750
150 0 1.1 1.6 94
0 0 1.1 1.6
<1
<1
1.2 7.6
— —
4, 47, F, 74 1—4
5—8
9—10
875
875
875
Mineralocorticoid initiation studies
0 0 3.0 1.0 70
150 0 2.0 1.0
150 0 3.0 1.0
<1
—
—
19.1 —
5.6 8.1
— —
5,48,M,76 1—7
8—12
750
750
0 0 3.1 1.2 95
150 0 1.8 1.2
<1
<1
9.8 26.6
— —
6,47, F, 53 1—5
6—10
750
750
0 0 2.9 1.9 131
0 120 2.9 1.9
<1
11
9.8 20.5
2.6 5.3
a Values of plasma renin activity (in nglmllhr) in our laboratory for normal subjects ingesting
dietary sodium were: ages 42 to 62, N 9, PRA 0.1 to 0.6 (supine), 0.9 to 7.9 (upright).
Dex is dexamethasone, Fludro is fludrocortisone, Aldo is aldosterone.
1.8 0.3 SD mEq/kg body wt per day
177 mI/minhl.73 m2
.t
5.0
32
—
4.0
28
ac
24'
0-
+10 - •40
0
D-—io- ---40 —
Ui —
—20- -—80
z
-1
—30 - —120
—40 IA - —160
--200
11111111 Jill 1111111 liii
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Time, days
Fig. 1. Representative study of the effect of discontinuation of
mineralocorticoid replacement therapy in an adrenalectomized
patient without apparent intrinsic renal disease (patient no. I).
The dashed line in the upper panel represents the mean control
value of both plasma total carbon dioxide and potassium con-
centration (PK). Values of net acid excretion (NAE) repre-
sent the difference between the daily net acid and the mean con-
trol values. Values of A net acid excretion (INAE) represent
the accumulated sum of the daily values of net acid excretion
during the period of mineralocorticoid discontinuation.
balance was temporally associated with a large in-
crease in sodium chloride intake.
The reduction in NAE following mineral-
ocorticoid discontinuation was accounted for in
part by an increase in urinary bicarbonate
(LHCO, +61 mEq) and in part by decreases in
urinary titratable acid (LTA, —49 mEq) and am-
monium (NH, —86 mEq).
In association with the observed reduction in net
acid excretion, a small but significant reduction oc-
curred in venous plasma total carbon dioxide( plasma total C02, —1.7 mmoles/liter; plasma
total CO2 control vs. days 5-8, 29.8 0.3 vs. 28.1
0.4 mmoles/liter, P < 0.02) (Fig. 1, Table 2). There
was no tendency for the reduced values of plasma
total CO2 to return toward control throughout the
11-day period of mineralocorticoid discontinuation.
Arterialized blood hydrogen ion concentration in-
creased slightly (Table 2). No significant change
occurred in plasma anion gap.
In the control period, mean urinary potassium ex-
cretion was 70 1 mEq/day; the daily values dif-
fered from the mean by no more than 7 mEq/day.
During the first 4 days following mineralocorticoid
discontinuation, daily potassium excretion de-
creased from the mean control value by 12 to 18
mEq. Thereafter, potassium excretion returned to
values virtually identical to control. This apparent
reestablishment of balance occurred prior to the
large increase in sodium chloride intake that was
initiated on the 9th day following mineralocorticoid
discontinuation. The cumulative retention of uri-
nary potassium was 74 mEq, and was associated with
a sustained significant increase in plasma potassium
concentration (3.8 0.0 vs. 4.3 0.1 mEq/liter, P
<0.001, control vs. days 5-8).
Following mineralocorticoid discontinuation, a
significant increase in urinary sodium and chloride
excretion occurred (Na, +609 mEq; Cl,
+396 mEq; day 8), accompanied by a significant re-
duction in plasma sodium and chloride concentra-
tion (PNa, 139 1 vs. 133 2 mEq/liter, P < 0.005;
Pci, 104 0.4 vs. 99 0.8 mEqiliter, P < 0.001).
Plasma renin activity was within normal limits with
respect to posture and dietary sodium prior to mm-
eralocorticoid discontinuation, and increased to su-
pernormal values following mineralocorticoid dis-
continuation (Table 1). In response to a large in-
crease in sodium intake (days 9-11 of
mineralocorticoid discontinuation), urinary sodium
increased to approximate intake, and plasma so-
dium concentration (136 mEq/Iiter) and renin activi-
ty (2.4 ng/ml/hr, upright) returned toward control
(day 11).
Summary of results for entire group: (a) Acid-
base changes. Within 24 hours of discontinuing
mineralocorticoid replacement in each patient (pa-
tients 1—3), urine pH increased, and the urinary ex-
cretion rates of titratable acid, ammonium, and net
acid decreased (Fig. 2). Conversely, within 24 hours
of initiating mineralocorticoid replacement in each
patient (patients 4—6), urine pH decreased, and the
excretion rates of titratable acid, ammonium, and
net acid increased (Fig. 2). Because the directional
change in each of these indexes of urine acid-base
composition was indicative of a positive effect of
mineralocorticoid on acidification in every patient,
the magnitude of the change in each index was used
without regard for sign for purposes of statistical
testing. Averaging the absolute values of the dif-
ferences between mineralocorticoid-replete and -de-
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Table 2. Acid-base effects of discontinuation or initiation of mineralocorticoid replacement therapy in glucocorticoid-replete
adrenalectomized patients without intrinsic renal disease
Cumu-
A Plasma A Arterial- lative
Pa-
Venous total CO2
plasma mmoleslliter
ized
blood
Initial Cumulative change
net acid change in in Na
tient Mineralocorticoid total CO2 —_--- [H] excretion net acid balancet
no. dose mmoleslliter Day 5 Days 4-5 nEqiliter mEq/day inEq mEq
I Fludrocortisone 100 tg/day
Mineralocorticoid discontinuation studies
29.8 0.3 80,3 1.8
Discontinued
dayl —38
day3 94
day5 28.7 —1.1 —1.2 +1.7 —145 —400
2 Fludrocortisone200g/day 29.6 0.4 63.1 2.0
Discontinued
dayl — 10
day3 — 30
day5 29.0 —0.6 —0.5 — 57 — 16
3 Fludrocortisone 150 pg/day 29.6 0.4 37.2 1.4
dayl —23
day3 28.9 —0.7 —1.3 — 41 —230
4 Mineralocorticoid—none
Mineralocorticoid institution studiesd
26.9 0.3 55.3 0.7
Initiate fiudrocortisone 150 gIday
dayl + 10
day3 + 38
dayS 27.6 +0.7 +1.2 —1.8 + 42 +229
5 Mineralocorticoid—none 28.1 0.2 63.6 1.0
Initiate fludrocortisone 150 jgIday
dayl + 3
day3 + 19
day5 29.3 +1.2 +0.8 —0.9 + 47 + 13
6 Mineralocorticoid—none 23.8 0.4 41.6 2.1
Initiate aldosterone 120 ag/day
dayl + 13
day3 + 26
dayS 26.4 +2.6 +2.4 —7.1 + 37 +456
Combined groupse (N = 6) IANAE
Mean of absolute values of A and A 1.2 0.3 1.2 0.3
P<0.02 P<0.01
(day 5) (days 4-5)
day 1, 16 5, P <0.05
day3,41 ll,P<0.02
day 5, 66 20, P < 0.05
Inpatient no. 3, data for days 3 and 2 to 3 are used owing to dietary noncompliance after day 3; in patients no. 2 and 6, data for days 5
and 6 are used instead of days 4 and 5 because day 4 blood specimens were not drawn.
h Cumulative change in sodium balance is the accumulated daily external balance calculated solely from changes in urinary excretion
relative to intake.
Values during mineralocorticoid therapy are steady-state values prior to discontinuation of mineralocorticoid therapy.
Values prior to mineralocorticoid initiation are steady-state values.
"A Plasma total CO2 and ANAE represent the average of their absolute values for the two groups of patients combined; P values in-
dicate the probability of a significant difference from zero.
prived states in the six patients, we found the
changes in urine pH and excretion of titratable acid,
ammonium, and net acid to be statistically signifi-
cant: pH = 0.31 0.02, P < 0.001; zTA = 7 3
mEq/day, P < 0.005; zNH4 = 5 2 mEq/day, P <
0.05; LNAE = 16 5 mEq/day, P < 0.05.
Following day 1 and throughout the subsequent
period of observation, the cumulative change in net
acid excretion (NAE) remained negative in each
patient in whom mineralocorticoid replacement was
discontinued and remained positive in each patient
in whom mineralocorticoid replacement was insti-
tuted (Table 2). Combining the results in the two
groups and averaging the absolute values, we found
the cumulative change in net acid excretion
(LNAE) to be 41 11 mEq (P < 0.02) by day 3
following the experimental maneuver. By day 5,
NAE was 66 20 mEq, P < 0.05. A significant
positive correlation was observed between the mag-
nitude of the cumulative change in NAE (4NAE)
in each patient and the corresponding mean value of
NAE measured prior to discontinuation or initiation
of therapy (r = 0.85, P < 0.05; dayS) (Fig. 3).
The findings in the patient who had the longest
period of mineralocorticoid deprivation (patient no.
2, 14 days) are shown in Fig. 4. Throughout the pro-
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Fig. 2. Effect of discontinuation or initiation or mineralocorticoid
replacement therapy on urine pH and the excretion rates of titra-
table acid (TA), ammonium, and net acid (NAE) in six adrenal-
ectomized patients without apparent intrinsic renal disease. Val-
ues represent change from mean control value on the first day
following discontinuation or initiation of mineralocorticoid.
longed period of observation, net acid excretion re-
mained below control. There was no tendency for
the cumulative reduction in net acid excretion that
occurred during the first half of the mineralocor-
ticoid deprivation period to be counterbalanced
by an increase in net acid excretion to values ex-
ceeding control during the second half of the miner-
alocorticoid deprivation period. Elimination of hy-
drogen ion retained initially following mineralo-
corticoid withdrawal also was not observed during
the course of prolonged mineralocorticoid depriva-
tion in patient no. 1 (11 days), in whom net acid
excretion returned to control, but not to values ex-
ceeding control, during the final period of observa-
tion (Fig. 1). The period of observation in the re-
maining patients was of insufficient duration to pro-
vide information concerning long-term (> 14 days)
renal acid-base effects of mineralocorticoid defi-
ciency.
Venous plasma total CO2 decreased in each patient
following mmeralocorticoid withdrawal and increased
in each patient following mineralocorticoid institution
(Table 2, Fig. 5). For the two groups of patients com-
bined, the absolute value of the change in plasma to-
tal CO2 averaged 1.2 0.3 mEq/liter (P <0.02) by
day 5 following discontinuation or institution of
Basal NAE, mEq/day
40 80
Fig. 3. Relation between cumulative change in net acid excretion(.NAE) and the initial rate of net acid excretion prior to dis-
continuation or initiation of mineralocorticoid replacement ther-
apy in six adrenalectomized patients without renal disease. Be-
cause the directional change in net acid excretion in every pa-
tient was indicative of a negative effect of mineralocorticoid
deficiency on acidification regardless of the order of the two ex-
perimental periods, NAE was plotted as a decrement in each
case. The magnitude of IANAE was used without regard for sign
for purposes of regression analysis. Values plotted represent the
5th experimental day except for patient no. 3 in whom only 3
days of experimental observation were obtained.
mineralocorticoid therapy. These changes did not
reflect primary changes in the respiratory com-
ponent of systemic acid-base equilibrium as judged
from the observed directional change in blood hy-
drogen ion concentration in four patients in whom
measurements of arterialized blood pH were ob-
tained. A significant positive correlation was ob-
served between the change in plasma total carbon
dioxide and the corresponding cumulative change in
net acid excretion in the six patients: z plasma total
CO2 = 0.015 . INAE + 0.64, r = 0.83, P < 0.05
(day 5) (Fig. 5).
(b) Relation of acid-base changes to changes in
sodium balance. The observed changes in both NAE
and plasma total CO2 correlated positively with the cor-
responding changes in sodium balance calculated
from the change in sodium excretion relative to in-
take: NAE = — 21.3 + 0.20 . Na balance, r
= 0.82, P <0.05; z plasma total CO2 = 0.31 + 0.004
Na balance, r = 0.90, P <0.05 (day 5) (Fig. 6).
The relation between changes in net acid excretion and
sodium balance was further evaluated in one patient
20
—30 —
I I I
.E
w
z
—60 —
—120 —
—180 -
r 0.85
P <0.05
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Fig. 4. Effect of a prolonged period (14 days) of mineralocorti-
coid discontinuation in an adrenalectomized patient without in-
trinsic renal disease (patient no. 2) in whom dietary sodium chlo-
ride was increased simultaneous with discontinuation of miner-
alocorticoid in an attempt to prevent negative sodium balance.
Values of excretion represent the differences between the daily
excretion values and the corresponding mean control values.
Values of I excretion represent the accumulated sum of the
daily values of excretion during the period of mineralocorticoid
discontinuation. Values of zi sodium balance were calculated
from the changes in urinary sodium excretion relative to intake.
in whom mineralocorticoid therapy was discontin-
ued for a period of 14 days, throughout which peri-
od sodium chloride intake was greatly increased in
an attempt to prevent negative sodium balance (Fig.
4). During most of the period of mineralocorticoid
deprivation, the cumulative sodium balance was ei-
ther positive or near zero, yet net acid excretion re-
mained below control such that the decrement from
control (LNAE) accumulated progressively at a
nearly constant rate (Fig. 4).
(c) Relation of acid-base changes to changes in
potassium balance. The effect of institution or dis-
II
NAE
+200 mEq
Fig. 5. Relation between change in plasma carbon dioxide con-
tent and the cumulative change in urinary net acid excretion
(ANAE, mEq) following the first 5 days of discontinuation
or initiation of mineralocorticoid replacement therapy in six
adrenalectomized patients without apparent intrinsic renal dis-
ease. In one patient (patient no. 3) the duration of study was only
3 days.
continuation of mineralocorticoid therapy on net
acid excretion in relation to changes in potassium
metabolism for the entire group is shown in Fig. 7.
During the first 3 days, a significant negative corre-
lation was observed between changes in daily net
acid excretion and the corresponding cumulative
changes in potassium balance as calculated from the
change in urinary potassium excretion relative to in-
take. Similarly, a significant negative correlation
was observed between the changes in daily net acid
excretion and the corresponding changes in plasma
potassium concentration. With chronicity of miner-
alocorticoid discontinuation, these correlations
may not persist, as is evidenced by the finding in
patient 2 of a persisting reduction in net acid excre-
tion in association with delayed reversal of the ini-
tially observed retention of urinary potassium (Fig.
4).
Discussion
The findings in the present study indicate that dis-
continuation of mineralocorticoid replacement ther-
apy in adrenalectomized patients maintained on
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Fig. 6. Relation between change in plasma carbon dioxide con-
tent and the cumulative change in sodium balance (A.Na+ bal-
ance, mEq) following the first 5 days of discontinuation or
initiation of mineralocorticoid replacement therapy in six adren-
alectomized patients without apparent intrinsic renal disease.
The changes in sodium balance were calculated from the changes
in urinary sodium excretion relative to intake. In one patient
(patient no. 3), the duration of study was only 3 days.
glucocorticoid replacement leads to a reduction in
net acid excretion and plasma bicarbonate concen-
tration, and that initiation of therapy leads to the
opposite effect. These results provide the first evi-
dence in adult humans without kidney disease that
mineralocorticoid at levels not exceeding those ob-
served in normal subjects critically modulates renal
acid-base homeostasis and thereby contributes to
maintenance of normal systemic acid-base equilibrium
under conditions of normal dietary sodium and po-
tassium and acid load.
Interpretation of the present results as reflecting
an acid-base effect of normal or low levels of miner-
alocorticoid is based in part on the estimated al-
dosterone potency-equivalence of the synthetic
mineralocorticoid steroid, fludrocortisone, and the
magnitude of the resultant mineralocorticoid effect
of the fludrocortisone administered as reflected by
plasma renin activity and plasma sodium and potas-
sium concentration. Fludrocortisone is estimated to
have nearly identical mineralocorticoid potency as
aldosterone [20-24]. The commonly used replace-
ment dose of fludrocortisone in patients with Add-
ison's disease (50 to 150 p,g/day) [20, 21, 25, 26] is
nearly identical to the secretion rate of aldosterone
observed in normal subjects on a liberal sodium in-
take (60 to 168 jsglday, 2 SD) [27]. In the dose
range of fludrocortisone used in the present study,
plasma renin activity was normal or slightly in-
creased and substantially lower than that observed
when mineralocorticoid was withheld (Table 1). 1
Plasma renin activity provides an index of "ef-
fective" extracellular fluid volume and therefore of
the adequacy of mineralocorticoid replacement [26,
28].
Estimation of the aldosterone potency-equiva-
lence of fludrocortisone is not the only basis for in-
terpretation of these results as reflecting the renal
acid-base effect of normal mineralocorticoid levels.
In one mineralocorticoid-deprived adrenalectomized
subject (patient no. 6), an increase in net acid ex-
cretion and plasma bicarbonate concentration oc-
curred when mineralocorticoid replacement was ef-
fected by constant infusion of the major naturally
occurring mineralocorticoid hormone, aldosterone.
The amount of aldosterone administered (120 sg/
day) approximated that ordinarily secreted in nor-
mal subjects at comparable levels of dietary so-
dium and potassium [27]. This amount of aldoste-
rone did not provide over-replacement inasmuch as
plasma renin activity was not reduced to subnormal
levels (Table 1).
It might be argued that the present results do not
establish whether the level of mineralocorticoid that
provides the observed tonic stimulation of renal
acidification is in the "physiologic" range inasmuch
as the observed renal acidosis-producing effect of
mineralocorticoid deficiency was evidenced during
the state of presumed complete mineralocorticoid
lack. Conceivably, a fully expressed tonic stimula-
tion of acidification is provided with mineralo-
corticoid at low levels only a small fraction of nor-
mal, whereas at higher levels within the "physio1og-
ic" range small deviations in mineralocorticoid
level may have little effect on acidification. Never-
theless, the present results establish that renal acid-
ification is under tonic stimulation by mineralo-
corticoid at levels that do not exceed those ob-
served in normal subjects ingesting diets of normal
sodium and potassium content. Furthermore, the
results permit the inference that under conditions of
normal dietary acid loads neither glucocorticoid
deficiency nor renal disease are prerequisites for ex-
pression of the renal acidosis-producing effect of
mineralocorticoid deficiency.
One subject required a fludrocortisone replacement dose of
200 sg per day to prevent postural hypotension and marked hy-
perreninemia; such a fludrocortisone requirement is not unprece-
dented among patients with Addison's disease [25, 26].
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Fig. 7. Relation between daily net acid excretion (MIAE) and
the cumulative change in potassium balance (upper panel) and
the change in plasma potassium concentration (lower panel)fol-
lowing discontinuation or institution of mineralocorticoid re-
placement therapy (days 1—3) in six adrenalectomized patients
without apparent intrinsic renal disease. Values of excretion,
balance, and concentration represent the difference between the
daily values of excretion, balance, and concentration, respec-
tively, and the corresponding mean control values. The changes
in potassium balance were calculated from the changes in urinary
potassium excretion relative to intake; values of cumulative
potassium balance represent the accumulated sum of the daily
values of potassium balance during the period of mineralocorti-
coid discontinuation.
The magnitude of the changes in plasma total car-
bon dioxide (0.6 to 2.6 mmoles/liter) that occurred
in response to discontinuation or initiation of miner-
alocorticoid therapy indicates a relatively small ton-
ic effect of mineralocorticoid on systemic acid-base
equilibrium. The magnitude of the decrement in
plasma bicarbonate concentration resulting from
lack of mineralocorticoid activity in the present
subjects is similar to the magnitude of the increment
(1 to 3 mEq/liter) observed in normal subjects dur-
ing prolonged administration of superphysiologic
amounts of aldosterone [8]. Taken together, these
results indicate that within the range from zero to
superphysiologic levels of aldosterone, there exists
an aldosterone-dependent range of variation of
plasma bicarbonate concentration of approximately
5 mEq/liter in normal subjects eating normal diets.
In these studies the change in plasma carbon
dioxide content following discontinuation or initia-
tion of mineralocorticoid replacement correlated
positively with the cumulative change in net acid
excretion (Fig. 5). Further, the change in net acid
excretion correlated with the control rate of net acid
excretion (Fig. 3). Taken together, these findings
suggest that the severity of the renal acidosis-pro-
ducing effect of mineralocorticoid deficiency is
greatest in those individuals with the largest endog-
enous acid loads, given that steady-state net acid
excretion normally reflects the rate of endogenous
acid production [29, 30]. These considerations raise
the possibility that the modulating role of physiolog-
ic levels of aldosterone would become critical in
clinical conditions in which endogenous acid pro-
duction is abnormally high, for example, lactic aci-
dosis, diarrhea. Plasma aldosterone concentration
is characteristically increased in acute diabetic ke-
toacidosis [31], and aldosterone secretion in normal
subjects ordinarily increases when the systemic
acid load is increased by exogenous acid loading
[32—34]. Further studies are required to elucidate
the role of aldosterone in the defense of systemic
acid-base equilibrium in clinical states of increased
acid production, and to investigate the mechanism
whereby aldosterone secretion is increased in re-
sponse to exogenous acid loading [35].
The potential deleterious effects of a small but
lifelong reduction in plasma bicarbonate concentra-
tion requires consideration. A persisting reduction
in plasma bicarbonate concentration of even 1 to 2
mEq/liter cannot be dismissed as benign because
the metabolic consequences of chronic metabolic
acidosis remain to be completely defined and are
probably not inconsequential [36-47]. In consid-
ering the possible deleterious effects of chronic
metabolic acidosis, we might make a distinction be-
tween acidemia and acid retention by the kidney. In
patients with familial proximal renal tubular acido-
sis, it has been reported that a progressively accu-
mulating positive hydrogen ion balance does not oc-
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cur owing to the excretion of net acid at normal
rates in the steady-state, yet negative calcium bal-
ance and metabolic bone disease common in other
states of chronic metabolic acidosis are not present
despite persisting acidemia [48]. Whether the ab-
sence of a progressively accumulating positive acid
balance lessens the risk of acidosis-related derange-
ments of metabolism is not known. The present
studies were not designed to investigate the rela-
tionship between chronicity of mineralocorticoid
deficiency and acid balance.
The mechanism whereby mineralocorticoid defi-
ciency caused a reduction in net acid excretion in
the present studies was not specifically investi-
gated. Conceivably, the predominant pathogenetic
factor is the reduction in renal sodium reabsorption
that results from mineralocorticoid deficiency. So-
dium depletion is a potential acidosis-producing fac-
tor by virtue of its effect to diminish delivery of so-
dium to the distal nephron. Pre-existing sodium de-
pletion limits the acid excretory response to
mineralocorticoid administration [1, 49]. In the
present studies, the changes in net acid excretion
correlated positively with the corresponding cu-
mulative changes in sodium balance, as calculated
from the changes in urinary excretion relative to in-
take. These findings are consistent with the hypoth-
esis that the changes in net acid excretion are sec-
ondary, at least in part, to the alterations in sodium
transport that result from the change in mineralo-
corticoid therapy. In one study of mineralocor-
ticoid discontinuation, however, net acid ex-
cretion and plasma bicarbonate concentration de-
creased even when sodium depletion was prevented
by adjustment of intake (Table 2, Fig. 4). Con-
versely, in one study in which mineralocorticoid
was initiated, net acid excretion and plasma bi-
carbonate concentration increased even when so-
dium retention was prevented (Table 2). Hence, the
tonic effect of mineralocorticoid on renal acid-
ification may not be mediated solely through modu-
lation of sodium balance. The reduction in net acid
excretion that occurs in mineralocorticoid-deficient
dogs [50] is not dependent on the depletion of so-
dium induced by mineralocorticoid deficiency [51],
but this does not appear to be the case in rats [52],
and remains to be tested in humans.
Further studies are required to assess the role of
altered sodium chloride balance in mediating the
renal acid-base response to mineralocorticoid defi-
ciency in humans. Even though negative sodium
balance and consequent reduced distal nephron so-
dium delivery are prevented during mineralocorti-
coid deficiency by appropriate increase in sodium
chloride intake, reduced rates of sodium reabsorp-
tion in the distal nephron persist and might compel a
persisting reduction in distal hydrogen ion secretion
[53—56]. In mammalian species, the existence of a
sodium-dependent mineralocorticoid-stimulated dis-
tal acidification process is consistent with the re-
sults of clearance and micropuncture studies that
relate urinary acidification to distal sodium supply,
anion absorbability, and mineralocorticoid activity
[57, 58]. Nevertheless, a sodium transport-mediated
acidification process has not been identified in the
mammalian distal nephron [59].
Hyperkalemia secondary to potassium retention
is another potential acidosis-producing con-
sequence of mineralocorticoid deficiency. Potas-
sium loading diminishes renal ammonia production
[60] and net renal bicarbonate reabsorptive capacity
[61] in the mammalian kidney. Evidence has been
adduced that hyperkalemia is a significant acidosis-
producing factor in patients with hypoaldosteron-
ism secondary to chronic renal disease and associ-
ated impaired renin secretion [62]. The role of po-
tassium in the present studies was not specifically
investigated. For the group as a whole, the changes
in daily net acid excretion were observed to corre-
late negatively with the corresponding cumulative
changes in potassium balance calculated from the
changes in urinary excretion relative to intake (Fig.
7). A similar negative correlation between the
changes in net acid excretion and plasma potassium
concentration was observed (Fig. 7). These findings
are consistent with the hypothesis that the changes
in net acid excretion are secondary, at least in part,
to the alterations in potassium transport that result
from the change in mineralocorticoid therapy. Fur-
ther studies are needed to assess the influence of
potassium balance inasmuch as, with chronicity of
mineralocorticoid discontinuation in one patient, a
persisting reduction in net acid excretion was ob-
served despite elimination of the retained potassium
that occurred initially (Fig. 4).
Whatever the mechanism whereby mineralo-
corticoid hormones modulate renal acidification,
the findings in this study provide the first evidence
that renal acidification is under tonic stimulation by
mineralocorticoid at levels not exceeding those that
prevail in normal subjects ingesting acid-producing
diets of normal sodium and potassium content. The
findings implicate mineralocorticoid deficiency as a
significant renal acidosis-producing condition not
dependent on the presence of intrinsic renal disease
or glucocorticoid deficiency, and potentially ampli-
772 Sebastian et al
fled when endogenous acid production is increased
by diet or disease.
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